Company intelligence / Profile preview

Transcenta

Ownership: Public · 06628
Employees: ~88
Development stage: Phase 3

Overview

Transcenta has a broad pipeline of over ten biologic programs focused on oncology and selected non-oncology indications such as bone and kidney diseases. Its lead program Osemitamab (TST001), targeting CLDN18.2 for gastric/gastroesophageal cancer, has reached global Phase III pivotal trials in combination with Nivolumab and chemotherapy. The company collaborates with Agilent Technologies for companion diagnostics development.[3][7] Other programs are at various clinical stages.

Therapeutic areas: OncologyNephrologyRheumatology
Modalities: Monoclonal antibodies (mAbs)Antibody-based biotherapeutics[1][2][3][5][6]
Industry: Biotech

Drug pipeline

20 assets

osemitamab

19 more assets in the full pipeline.

Request access →

Partnerships

Agilent Technologies (companion diagnostic collaboration for CLDN18.2/Osemitamab)[7]

Beyond the preview

Go deeper on Transcenta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcenta.

Explore the full profile